The clinical characteristics, initial presentation, management, and outcomes of patients hospitalized with new-onset (first diagnosis) heart failure (HF) or decompensation of chronic HF are poorly understood worldwide. REPORT-HF is a global, prospective, and observational HF disease registry designed to characterize patient trajectories longitudinally during and following an index hospitalization for acute HF.
Study Type
OBSERVATIONAL
Enrollment
18,805
Number of patients with different characteristics of heart faliure (HF) at hospitalization
Time frame: From admission to discharge of the patient's index hospitalization (minimum 24 hours)
Percentage of patients who die during the index hospitalization
Time frame: From admission to discharge of the patient's index hospitalization (minimum 24 hours)
Percentage of patients who die during the follow-up period post-discharge
Time frame: up to 3 years
Percentage of patients who are re-hospitalized by primary re-hospitalization reason (Cardiovascular and non-Cardiovascular)
Time frame: up to 3 years
Number of patients with different characteristics of post-discharge patient management
Time frame: up to 3 years
Healthcare Resource Utilization assessed by number of patients with re-hospitalizations
Time frame: up to 3 years
Health-related Quality of life (HRQoL) based on patient reported data as measured by EQ-5D and the Kansas City Cardiomyopathy Questionnaire (KCCQ) questionnaires
Time frame: up to 3 years
Caregiver burden based on Caregiver Burden Questionnaire -Heart Failure (CBQ-HF) and Work Productivity and Activity Impairment (WPAI) questionnaires
Time frame: up to 3 years
Correlation ratio between practice patterns and outcomes
Time frame: up to 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Novartis Investigative Site
San Diego, California, United States
Novartis Investigative Site
San Francisco, California, United States
Novartis Investigative Site
Chicago, Illinois, United States
Novartis Investigative Site
Indianapolis, Indiana, United States
Novartis Investigative Site
Kansas City, Kansas, United States
Novartis Investigative Site
New Orleans, Louisiana, United States
Novartis Investigative Site
New Orleans, Louisiana, United States
Novartis Investigative Site
Detroit, Michigan, United States
Novartis Investigative Site
Detroit, Michigan, United States
Novartis Investigative Site
Jackson, Mississippi, United States
...and 336 more locations